Literature DB >> 20861136

K14 mRNA reprogramming for dominant epidermolysis bullosa simplex.

Verena Wally1, Marietta Brunner, Thomas Lettner, Martin Wagner, Ulrich Koller, Andrea Trost, Eva M Murauer, Stefan Hainzl, Helmut Hintner, Johann W Bauer.   

Abstract

The major challenge to a successful gene therapy of autosomal dominant genetic diseases is a highly efficient and specific knock-down or repair of the disease-causing allele. In epidermolysis bullosa simplex-type Dowling-Meara (EBS-DM), a single amino acid exchange in exon 1 of the keratin 14 gene (K14) triggers a severe skin phenotype, characterized by blistering of the skin and mucous membranes after minor trauma. We chose spliceosome-mediated RNA trans-splicing to specifically replace exons 1-7 of the K14 gene. In this approach, the mutated coding region is replaced by an RNA-trans-splicing molecule (RTM) that incorporates a binding domain (BD) and the wild-type sequence of K14. Since the BD is crucial for the trans-splicing functionality, we developed a fluorescence-based RTM screen consisting of an RTM library containing random BDs. Co-transfection of the library with a target molecule enabled us to identify highly functional RTMs. The best RTMs were adapted for endogenous trans-splicing in an EBS-DM patient cell line. In this cell line, we were able to detect functional, efficient and correct trans-splicing on RNA and protein levels. Scratch assays confirmed phenotypic reversion in vitro. Owing to concomitant knock-down and repair of the mutated allele, we assume that trans-splicing is a promising tool for the treatment of autosomal dominant genetic disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861136     DOI: 10.1093/hmg/ddq405

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  28 in total

1.  The design and optimization of RNA trans-splicing molecules for skin cancer therapy.

Authors:  Christina Gruber; Ulrich Koller; Eva M Murauer; Stefan Hainzl; Clemens Hüttner; Thomas Kocher; Andrew P South; Helmut Hintner; Johann W Bauer
Journal:  Mol Oncol       Date:  2013-08-19       Impact factor: 6.603

Review 2.  Gene therapy for skin diseases.

Authors:  Emily Gorell; Ngon Nguyen; Alfred Lane; Zurab Siprashvili
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

Review 3.  Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise.

Authors:  Jean Christopher Chamcheu; Gary S Wood; Imtiaz A Siddiqui; Deeba N Syed; Vaqar M Adhami; Joyce M Teng; Hasan Mukhtar
Journal:  Exp Dermatol       Date:  2012-07       Impact factor: 3.960

4.  A Gene Gun-mediated Nonviral RNA trans-splicing Strategy for Col7a1 Repair.

Authors:  Patricia Peking; Ulrich Koller; Stefan Hainzl; Sophie Kitzmueller; Thomas Kocher; Elisabeth Mayr; Alexander Nyström; Thomas Lener; Julia Reichelt; Johann W Bauer; Eva M Murauer
Journal:  Mol Ther Nucleic Acids       Date:  2016-03-01       Impact factor: 10.183

5.  A novel screening system improves genetic correction by internal exon replacement.

Authors:  Ulrich Koller; Verena Wally; Lloyd G Mitchell; Alfred Klausegger; Eva M Murauer; Elisabeth Mayr; Christina Gruber; Stefan Hainzl; Helmut Hintner; Johann W Bauer
Journal:  Nucleic Acids Res       Date:  2011-06-17       Impact factor: 16.971

Review 6.  Defining keratin protein function in skin epithelia: epidermolysis bullosa simplex and its aftermath.

Authors:  Pierre A Coulombe; Chang-Hun Lee
Journal:  J Invest Dermatol       Date:  2012-01-26       Impact factor: 8.551

Review 7.  Pathogenetic Therapy of Epidermolysis Bullosa: Current State and Prospects.

Authors:  I I Ryumina; K V Goryunov; D N Silachev; Yu A Shevtsova; V A Babenko; N M Marycheva; Yu Yu Kotalevskaya; V V Zubkov; G T Zubkov
Journal:  Bull Exp Biol Med       Date:  2021-05-29       Impact factor: 0.804

Review 8.  RNA-based therapies for genodermatoses.

Authors:  Olivier Bornert; Patricia Peking; Jeroen Bremer; Ulrich Koller; Peter C van den Akker; Annemieke Aartsma-Rus; Anna M G Pasmooij; Eva M Murauer; Alexander Nyström
Journal:  Exp Dermatol       Date:  2017-01       Impact factor: 3.960

Review 9.  Investigational Treatments for Epidermolysis Bullosa.

Authors:  Ping-Chen Hou; Han-Tang Wang; Stasha Abhee; Wei-Ting Tu; John A McGrath; Chao-Kai Hsu
Journal:  Am J Clin Dermatol       Date:  2021-07-22       Impact factor: 7.403

10.  Trans-splicing correction of tau isoform imbalance in a mouse model of tau mis-splicing.

Authors:  María Elena Avale; Teresa Rodríguez-Martín; Jean-Marc Gallo
Journal:  Hum Mol Genet       Date:  2013-03-03       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.